Lipocine Balance Sheet Health
Financial Health criteria checks 6/6
Lipocine has a total shareholder equity of $19.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $20.7M and $1.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$19.82m |
| Equity | US$19.12m |
| Total liabilities | US$1.58m |
| Total assets | US$20.70m |
Recent financial health updates
Does Lipocine (NASDAQ:LPCN) Have A Healthy Balance Sheet?
Feb 22
Is Lipocine (NASDAQ:LPCN) Using Debt Sensibly?
Sep 14Lipocine (NASDAQ:LPCN) Has Debt But No Earnings; Should You Worry?
Dec 04
Recent updates
Lipocine announces plans to focus on treating CNS disorders, shares rise ~5%
Sep 26Does Lipocine (NASDAQ:LPCN) Have A Healthy Balance Sheet?
Feb 22Is Lipocine (NASDAQ:LPCN) Using Debt Sensibly?
Sep 14Lipocine soars 9% on FDA greenlight for Phase 2 LPCN 1154 study in postpartum depression
Jun 14Lipocine competitor prevails in patent infringement lawsuit for Jatenzo
May 26When Will Lipocine Inc. (NASDAQ:LPCN) Turn A Profit?
May 11Lipocine EPS beats by $0.01
May 06Lipocine Inc. (NASDAQ:LPCN): Are Analysts Optimistic?
Jan 26Lipocine announces positive results from phase 2biopsy-confirmed NASH study
Jan 12FDA Ok's Lipocine's testosterone replacement therapy, tentatively
Dec 09Lipocine (NASDAQ:LPCN) Has Debt But No Earnings; Should You Worry?
Dec 04Lipocine EPS misses by $0.01
Nov 10Lipocine: TLANDO Might Become A Potential TRT Option In Patients With COVID-19 Infection
Nov 06Financial Position Analysis
Short Term Liabilities: LPCN's short term assets ($20.5M) exceed its short term liabilities ($1.6M).
Long Term Liabilities: LPCN has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: LPCN is debt free.
Reducing Debt: LPCN has no debt compared to 5 years ago when its debt to equity ratio was 105.7%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LPCN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: LPCN has sufficient cash runway for 2.9 years if free cash flow continues to grow at historical rates of 10.3% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/22 22:07 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lipocine Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| John Newman | Canaccord Genuity |
| Corey Davis | Canaccord Genuity |